Excited to share our new review paper on the role of the cerebellum in #MultipleSclerosis! We explore structural damage and network disconnections in MS, shedding light on the little brain. 🧠📚 Menno Schoonheim sciencedirect.com/science/articl…

Today we had a fantastic conversation with Tom Fuchs, of @AmsterdamUMC, who provided some background on the DAAE score and how this tool can be used in the #MS clinical practice. Stay tuned for the interview coming soon! 🧠🎥 MS Centrum Amsterdam Anatomy & Neurosciences

📹🫣 Here is a sneak peek at the interview that we did with Tom Fuchs, of @AmsterdamUMC, on how the DAAE score can be used as an effective and efficient tool in #MultipleSclerosis. #MS MS Centrum Amsterdam Anatomy & Neurosciences 🧠

Tom Fuchs, of @AmsterdamUMC, talked about the key predictors used in the DAAE score for assessing the risk of transition to secondary progressive #MS. MS Centrum Amsterdam Anatomy & Neurosciences neurologylive.com/view/developme…

So many insightful sessions about cognition in multiple sclerosis at the IMSCOGS conference in Bern, Switzerland! The experience of learning from the experts, pictured here.

Just published! Cognition in people with multiple sclerosis can worsen silently in periods without relapse. Objective testing can help us capture and understand this change. Thank you to ECTRIMS for their support, to IMSCOGS for featuring this research in Bern Switzerland, and

Thank you to Carmen Tur and Emilio Portaccio for their very nice editorial in MSJ about our work on cognitive progression independent of relapse in people with multiple sclerosis. In the article, Drs. Tur and Portaccio make interesting points and observations about

🗣️🎙️In our latest NeuroVoices, Tom Fuchs, MD, PhD, of Amsterdam UMC, talked about a tool that helps assess the likelihood of transitioning to secondary progressive #MS, allowing clinicians to make informed treatment decisions in a timely manner. 👉 neurologylive.com/view/neurovoic…

1/Have MULTIPLE questions about the new criteria for MULTIPLE sclerosis? ECTRIMS 2024 just came out w/proposed new changes to the McDonald criteria for multiple sclerosis. The changes are complex, but here is a thread w/the basics that you NEED to know!

My interview with Matt Hoffman NeurologyLive® in Copenhagen #ECTRIMS2024 is now available! We discussed personalized medicine for patients with multiple sclerosis and the DAAE Score 2.0, our improved clinical tool for estimating risk of transition to secondary progressive

In #MS, cognition can decline independent of relapse as well as independent of worsening physical disability, according to a study by Tom Fuchs of University at Buffalo MD-PhD Program & colleagues in MSJ. Read our Q&A here: buff.ly/3YahVY3 #SoMeDocs #NeuroTwitter

Cognitive progression independent of relapse is common in people with #MultipleSclerosis (68.1% of cognitive decline events). Retrospective study with 8 years of follow-up from Tom Fuchs MS Centrum Amsterdam Amsterdam UMC Jacobs School at University at Buffalo UBuffalo ▶️ journals.sagepub.com/doi/full/10.11… 1/🧵

How does cognitive testing contribute to personalized care for patients with multiple sclerosis? See my recent article in NeurologyLive® addressing this question bit.ly/cogforpersonal… This work supported by ECTRIMS Anatomy & Neurosciences MS Centrum Amsterdam

Disease progression in MS is predictable using clinically accessible information and technology. Congratulations to the brilliant Julia Jelgerhuis for this excellent work! And thank you to our wonderful partners in Prague who have been extraordinary scientific collaborators. The

By testing the SDMT monthly across 3 years, the plateau of practice effects was reached after 18 repetitions, suggesting that alternate versions and reliable-change methodologies should be considered. Study from Göteborgs universitet / University of Gothenburg Sahlgrenska Universitetssjukhuset ▶️ journals.sagepub.com/doi/full/10.11…

Thank you ECTRIMS for supporting this work, to the committee for honoring us with this award, and to my incredible mentors and collaborators! I am proud of this research, unraveling the functional brain underpinnings of disease progression in people with multiple sclerosis.